Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
mitogen-activated protein kinase
(
MAPK
) pathway is a conserved eukaryotic signaling module that converts receptor signals into various outputs.
MAPK
is activated through phosphorylation by
MAPK
kinase (MAPKK), which is first activated by MAPKK kinase (MAPKKK). A genetic selection based on a
MAPK
pathway in yeast was used to identify a mouse protein kinase (
TAK1
) distinct from other members of the MAPKKK family.
TAK1
was shown to participate in regulation of transcription by transforming growth factor-beta (TGF-beta). Furthermore, kinase activity of
TAK1
was stimulated in response to TGF-beta and bone morphogenetic protein. These results suggest that
TAK1
functions as a mediator in the signaling pathway of TGF-beta superfamily members.
...
PMID:Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. 853 96
A cDNA encoding a novel member of the mitogen-activated protein kinase kinase (MAPKK) family, MAPKK6, was isolated and found to encode a protein of 334 amino acids, with a calculated molecular mass of 37 kDa that is 79% identical to MKK3. MAPKK6 was shown to phosphorylate and specifically activate the p38/MPK2 subgroup of the
mitogen-activated protein kinase
superfamily and could be demonstrated to be phosphorylated and activated in vitro by
TAK1
, a recently identified MAPKK kinase. MKK3 was also shown to be a good substrate for
TAK1
in vitro. Furthermore, when co-expressed with
TAK1
in cells in culture, both MAPKK6 and MKK3 were strongly activated. In addition, co-expression of
TAK1
and p38/MPK2 in cells resulted in activation of p38/MPK2. These results indicate the existence of a novel kinase cascade consisting of
TAK1
, MAPKK6/MKK3, and p38/MPK2.
...
PMID:A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. 866 74
Ceramide has been proposed as a second messenger molecule implicated in a variety of biological processes. It has recently been reported that ceramide activates
stress-activated protein kinase
(
SAPK
, also known as c-Jun NH2-terminal kinase
JNK
), a subfamily member of
mitogen-activated protein kinase
superfamily molecules and that the ceramide/
SAPK
/
JNK
signaling pathway is required for stress-induced apoptosis. However, the molecular mechanism by which ceramide induces
SAPK
/
JNK
activation is unknown. Here we show that
TAK1
, a member of the mitogen-activated protein kinase kinase kinase family, is activated by treatment of cells with agents and stresses that induce an increase in ceramide. Ceramide itself stimulated the kinase activity of
TAK1
. Expression of a constitutively active form of
TAK1
resulted in activation of
SAPK
/
JNK
and SEK1/MKK4, a direct activator of
SAPK
/
JNK
. Furthermore, expression of a kinase-negative form of
TAK1
interfered with the activation of
SAPK
/
JNK
induced by ceramide. These results indicate that
TAK1
may function as a mediator of ceramide signaling to
SAPK
/
JNK
activation.
...
PMID:TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. 907 27
Transforming growth factor beta (TGF-beta)-activated kinase (
TAK1
) is known for its involvement in TGF-beta signaling and its ability to activate the p38-
mitogen-activated protein kinase
(
MAPK
) pathway. This report shows that
TAK1
is also a strong activator of
c-Jun N-terminal kinase
(JNK). Both the wild-type and a constitutively active mutant of
TAK1
stimulated JNK in transient transfection assays. Mitogen-activated protein kinase kinase 4 (MKK4)/
stress-activated protein kinase
/
extracellular signal-regulated kinase
(SEK1), a dual-specificity kinase that phosphorylates and activates JNK, synergized with
TAK1
in activating JNK. Conversely, a dominant-negative (MKK4/SEK1 mutant inhibited
TAK1
-induced JNK activation. A kinasedefective mutant of
TAK1
effectively suppressed hematopoietic progenitor kinase-1 (HPK1)-induced JNK activity but had little effect on germinal center kinase activation of JNK. There are two additional
MAPK
kinase kinases, MEKK1 and mixed lineage kinase 3 (MLK3), that are also downstream of HPK1 and upstream of MKK4/SEK mutant. However, because the dominant-negative mutants of MEKK1 and MLK3 did not inhibit
TAK1
-induced JNK activity, we conclude that activation of JNK1 by
TAK1
is independent of MEKK1 and MLK3. In addition to
TAK1
, TGF-beta also stimulated JNK activity. Taken together, these results identify
TAK1
as a regulator in the HPK1 -->
TAK1
--> MKK4/SEK1 --> JNK kinase cascade and indicate the involvement of JNK in the TGF-beta signaling pathway. Our results also suggest the potential roles of
TAK1
not only in the TGF-beta pathway but also in the other HPK1/JNK1-mediated pathways.
...
PMID:Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction. 927 37
Curcumin, a dietary pigment in curry, suppresses tumor initiation and tumor promotion. Curcumin is also a potent inhibitor for AP-1 and NF-kappaB activation. In this report, we show that curcumin inhibits
JNK
activation by various agonists including PMA plus ionomycin, anisomycin, UV-C, gamma radiation, TNF-alpha, and sodium orthovanadate. Although both
JNK
and ERK activation by phorbol 12-myristate 13-acetate (PMA) plus ionomycin were suppressed by curcumin, the
JNK
pathway was more sensitive. The IC50 (50% inhibition concentration) of curcumin was between 5-10 microM for
JNK
activation and was 20 microM for ERK activation. In transfection assays, curcumin moderately suppressed MEKK1-induced
JNK
activation; however, it effectively blocked
JNK
activation caused by co-transfection of
TAK1
, GCK, or HPK1. Curcumin did not directly inhibit
JNK
, SEK1, MEKK1 or HPK1 activity. Although curcumin suppressed
TAK1
and GCK activities at high concentrations, this inhibition cannot fully account for the
JNK
inhibition by curcumin in vivo. Our data suggest that curcumin may affect the
JNK
pathway by interfering with the signaling molecule(s) at the same level or proximally upstream of the MAPKKK level. Taken together, the inhibition of the MEKK1-
JNK
pathway reveals a possible mechanism of suppression of AP-1 and NF-kappaB signaling by curcumin, and may explain the potent anti-inflammatory and anti-carcinogenic effects of this chemical.
...
PMID:Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. 967 1
The yeast serine/threonine kinase STE20 activates a signaling cascade that includes STE11 (mitogen-activated protein kinase kinase kinase), STE7 (mitogen-activated protein kinase kinase), and FUS3/KSS1 (
mitogen-activated protein kinase
) in response to signals from both Cdc42 and the heterotrimeric G proteins associated with transmembrane pheromone receptors. Using degenerate polymerase chain reaction, we have isolated a human cDNA encoding a protein kinase homologous to STE20. This protein kinase, designated HPK/GCK-like kinase (HGK), has nucleotide sequences that encode an open reading frame of 1165 amino acids with 11 kinase subdomains. HGK was a serine/threonine protein kinase that specifically activated the
c-Jun N-terminal kinase
(JNK) signaling pathway when transfected into 293T cells, but it did not stimulate either the
extracellular signal-regulated kinase
or p38 kinase pathway. HGK also increased AP-1-mediated transcriptional activity in vivo. HGK-induced JNK activation was inhibited by the dominant-negative MKK4 and MKK7 mutants. The dominant-negative mutant of
TAK1
, but not MEKK1 or
MAPK
upstream kinase (MUK), strongly inhibited HGK-induced JNK activation. TNF-alpha activated HGK in 293T cells, as well as the dominant-negative HGK mutants, inhibited TNF-alpha-induced JNK activation. These results indicate that HGK, a novel activator of the JNK pathway, may function through
TAK1
, and that the HGK -->
TAK1
--> MKK4, MKK7 --> JNK kinase cascade may mediate the TNF-alpha signaling pathway.
...
PMID:A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. 989 Sep 73
Hematopoietic progenitor kinase 1 (HPK1), a mammalian Ste20-related protein kinase, is an upstream activator of
c-Jun N-terminal kinase
(JNK). In order to further characterize the HPK1-mediated JNK signaling cascade, we searched for HPK1-interacting proteins that could regulate HPK1. We found that HPK1 interacted with Crk and CrkL adaptor proteins in vitro and in vivo and that the proline-rich motifs within HPK1 were involved in the differential interaction of HPK1 with the Crk proteins and Grb2. Crk and CrkL not only activated HPK1 but also synergized with HPK1 in the activation of JNK. The HPK1 mutant (HPK1-PR), which encodes the proline-rich region alone, blocked JNK activation by Crk and CrkL. Dominant-negative mutants of HPK1 downstream effectors, including MEKK1,
TAK1
, and SEK1, also inhibited Crk-induced JNK activation. These results suggest that the Crk proteins serve as upstream regulators of HPK1. We further observed that the HPK1 mutant HPK1-KD(M46), which encodes the kinase domain with a point mutation at lysine-46, and HPK1-PR blocked interleukin-2 (IL-2) induction in Jurkat T cells, suggesting that HPK1 signaling plays a critical role in IL-2 induction. Interestingly, HPK1 phosphorylated Crk and CrkL, mainly on serine and threonine residues in vitro. Taken together, our findings demonstrate the functional interaction of HPK1 with Crk and CrkL, reveal the downstream pathways of Crk- and CrkL-induced JNK activation, and highlight a potential role of HPK1 in T-cell activation.
...
PMID:Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase. 989 Oct 69
Recent studies have revealed that
mitogen-activated protein kinase
(
MAPK
) consists of at least three subfamilies, namely classical
MAPK
(also known as ERK),
stress-activated protein kinase
/
c-Jun N-terminal kinase
(JNK) and p38 kinase. TGF-beta-activating kinase (TAK)-1 is a novel MAPKKK which is reported to stimulate p38K and/or the JNK pathway. To elucidate the functional roles of the
TAK1
pathway, we transfected its constitutive active form (TAK1dN) and negative form (TAK1K63W) into LLC-PK1 cells. TAKdN inhibited [3H]thymidine uptake and reduced the percentages of S and G2/M phases. TAK1K63W ameliorated the inhibitory effects of TGF-beta on [3H]thymidine uptake and increased the percentages of S and G2/M phases. Western blot analysis demonstrates that the level of cyclin D1 protein was regulated negatively by overexpression of TAK1dN. Moreover, overexpression of TAK1dN inhibited cyclin D1 promoter activity. In contrast, constitutive active MKK1, the classical p42/44
MAPK
activator, increased cyclin D1 promoter activity and level of protein. Overexpression of the active form of MKK1 increased [3H]thymidine uptake, while the inactive form decreased the uptake. In conclusion, cyclin D1 promoter activity and cell cycle progression are regulated negatively by the
TAK1
pathway and positively by the classical
MAPK
pathway.
...
PMID:Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. 1004 49
The signalling protein Wnt regulates transcription factors containing high-mobility-group (HMG) domains to direct decisions on cell fate during animal development. In Caenorhabditis elegans, the HMG-domain-containing repressor POP-1 distinguishes the fates of anterior daughter cells from their posterior sisters throughout development, and Wnt signalling downregulates POP-1 activity in one posterior daughter cell called E. Here we show that the genes mom-4 and lit-1 are also required to downregulate POP-1, not only in E but also in other posterior daughter cells. Consistent with action in a common pathway, mom-4 and lit-1 exhibit similar mutant phenotypes and encode components of the
mitogen-activated protein kinase
(
MAPK
) pathway that are homologous to vertebrate transforming-growth-factor-beta-activated kinase (
TAK1
) and NEMO-like kinase (NLK), respectively. Furthermore, MOM-4 and
TAK1
bind related proteins that promote their kinase activities. We conclude that a
MAPK
-related pathway cooperates with Wnt signal transduction to downregulate POP-1 activity. These functions are likely to be conserved in vertebrates, as
TAK1
and NLK can downregulate HMG-domain-containing proteins related to POP-1.
...
PMID:MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans. 1039 Dec 46
The Wnt signalling pathway regulates many developmental processes through a complex of beta-catenin and the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of high-mobility-group transcription factors. Wnt stabilizes cytosolic beta-catenin, which then binds to TCF and activates gene transcription. This signalling cascade is conserved in vertebrates, Drosophila and Caenorhabditis elegans. In C. elegans, the proteins MOM-4 and LIT-1 regulate Wnt signalling to polarize responding cells during embryogenesis. MOM-4 and LIT-1 are homologous to
TAK1
(a kinase activated by transforming growth factor-beta) mitogen-activated protein-kinase-kinase kinase (MAP3K) and
MAP kinase
(
MAPK
)-related NEMO-like kinase (NLK), respectively, in mammalian cells. These results raise the possibility that
TAK1
and NLK are also involved in Wnt signalling in mammalian cells. Here we show that
TAK1
activation stimulates NLK activity and downregulates transcriptional activation mediated by beta-catenin and TCF. Injection of NLK suppresses the induction of axis duplication by microinjected beta-catenin in Xenopus embryos. NLK phosphorylates TCF/LEF factors and inhibits the interaction of the beta-catenin-TCF complex with DNA. Thus, the
TAK1
-NLK-
MAPK
-like pathway negatively regulates the Wnt signalling pathway.
...
PMID:The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. 1039 Dec 47
1
2
3
4
5
6
7
8
9
10
Next >>